Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenue | 6,560 | — |
| Operating expenses | ||
| Research and development | 95,726 | 70,886 |
| General and administrative | 19,378 | 13,503 |
| Total operating expenses | 115,104 | 84,389 |
| Loss from operations | (108,544) | (84,389) |
| Other income | ||
| Interest income and other income, net | 10,005 | 12,211 |
Item 1. Financial Statements (UNAUDITED).
FAQ
- What is IDEAYA Biosciences, Inc.'s G&A?
- IDEAYA Biosciences, Inc. (IDYA) reported G&A of $19.38M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s G&A changed year-over-year?
- IDEAYA Biosciences, Inc.'s G&A increased by 43.5% year-over-year, from $13.5M to $19.38M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s G&A?
- Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s G&A has grown at a 33.3% compound annual growth rate (CAGR), from $20.05M to $63.32M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about IDEAYA Biosciences, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude